November 15, 2024
avatar-torie-bosch
First Opinion editor

It’s been a busy news week, to put it mildly. But I wanted to use today’s newsletter to highlight a First Opinion essay that you may have missed in the crush of post-election stories.

Jeff Karp has one of those bios that is a little overwhelming: a biomedical engineer, a professor of anesthesiology, co-founder of a dozen companies, dedicated mentor. (STAT profiled him back in 2018, when he had co-founded just six companies.)

He also has ADHD, as he shared in First Opinion this week. “By second grade, I had collected a series of labels: ‘lazy,’ ‘unmotivated,’ ‘disruptive,’ even ‘lost cause.’ My teacher, exasperated by my inability to conform, even wanted to hold me back,” he wrote. (Jeff, have you considered sending that teacher a printout of your Linkedin profile?)

But while others might talk about “overcoming” neurodivergence, he sees it differently. “For years, I viewed my ADHD as a deficit. Now, I recognize it as a source of strength, propelling me to explore uncharted territories, ask critical questions, and connect more deeply with the world around me.” In the essay, he shares insights into how he uses his creativity, hyperfocus, and deep emotions to come up with ideas and inspire others.

It's a powerful idea and just the type of essay I love to publish: It’s personal, well-written, and shares a surprising journey.

There’s no sign that the news environment will slow down, especially within STAT’s topic areas, and First Opinion will stay on top of, maybe even ahead of, the biggest stories in life sciences.

But even as the chaos of a new administration descends, I want to make sure that First Opinion continues to publish these important, thoughtful pieces — the kinds of essays that are sometimes called evergreen because they’re always fresh. As always, please share your thoughts and ideas at first.opinion@statnews.com.

Recommendation of the week: I’m late to this, but I recently binged both seasons of “Dr. Death” on Peacock, a show that is equal parts heartbreaking and enraging. (Oh, and a little terrifying, too.)

Jeff Karp, assistant professor of medicine and co-director of Regenerative Therapeutics, Department of Medicine, Brigham and Women's Hospital.
Courtesy

How ADHD wired me for scientific discovery

ADHD has profoundly shaped my journey as a scientist, from the setbacks of my early years to the discoveries I've made in my laboratory.

By Jeff Karp


FDA commissioner: We need action and higher-quality research on ultra-processed foods

FDA Commissioner Robert M. Califf and colleagues call for a concerted effort to tackle diet-related disease.

By Robert M. Califf, Haider J. Warraich, and Jim Jones


Tech and social media bans alone cannot fix teen mental health

Unless we’re content to play an endless game of whack-a-mole with new technologies, we need to look deeper on teen mental health.

By Emily Weinstein and Sara Konrath



Charlie Neibergall/AP

How chaplains can help the fractured U.S. health care system

Hospitals should support chaplains, who can aid countless patients and families facing impossible-seeming conversations and decisions.

By Robert Klitzman


STAT+ | How I addressed racial bias in my company’s AI algorithm

After watching a pulse oximeter struggle with my father’s dark skin before he died from Covid, making health care AI more trustworthy became my mission.

By Amber Nigam


Congress must act now to protect the future of diagnostic tests

To protect patients and give test developers a clearer regulatory environment, Congress should pass the VALID Act.

By Walter G. Johnson


Getting creative with health care in a new Trump administration

The health policy world needs to focus on issues that haven’t become overly politicized, Carmel Shachar said on this episode of the “First Opinion Podcast.”

By Torie Bosch


Invest in ‘triple rapid’ tests to fight mpox, H5N1 bird flu, and beyond

The international health community should develop, approve, and stockpile tests that offer rapid reconfiguration, deployment, and results.

By Janika Schmitt and Jacob Swett


A new Trump administration will further loosen already-lax rules on supplements

In the absence of meaningful regulation from the FDA, the supplement industry will no doubt take RFK Jr.’s stance as a free pass.

By S. Bryn Austin and Amanda Raffoul


More around STAT
Check out more exclusive coverage with a STAT+ subscription
Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

Enjoying First Opinion? Tell us about your experience
Continue reading the latest health & science news with the STAT app
Download on the App Store or get it on Google Play
STAT
STAT, 1 Exchange Place, Boston, MA
©2024, All Rights Reserved.